MCID: GNG008
MIFTS: 46

Ganglioneuroblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Ganglioneuroblastoma

MalaCards integrated aliases for Ganglioneuroblastoma:

Name: Ganglioneuroblastoma 12 58 54 6 44 15 17 70

Characteristics:

Orphanet epidemiological data:

58
ganglioneuroblastoma
Inheritance: Not applicable; Age of onset: Childhood,Infancy;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4163
MeSH 44 D018305
NCIt 50 C3790
SNOMED-CT 67 116381000119105
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 71 C0206718
Orphanet 58 ORPHA251877
UMLS 70 C0206718

Summaries for Ganglioneuroblastoma

MalaCards based summary : Ganglioneuroblastoma is related to nodular ganglioneuroblastoma and gangliocytoma. An important gene associated with Ganglioneuroblastoma is WASF3 (WASP Family Member 3), and among its related pathways/superpathways are Neuroscience and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Crizotinib and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and adrenal gland, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Ganglioneuroblastoma is a variant of neuroblastoma that is surrounded by ganglion... more...

Related Diseases for Ganglioneuroblastoma

Diseases related to Ganglioneuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)
# Related Disease Score Top Affiliating Genes
1 nodular ganglioneuroblastoma 31.9 NTRK2 MYCN ENO2 ALK
2 gangliocytoma 30.7 TH SYP ENO2 CRH
3 central hypoventilation syndrome, congenital 30.7 TH PHOX2B NTRK2 MYCN HTR1A ALK
4 retroperitoneal neuroblastoma 30.0 MYCN ENO2
5 neuroendocrine tumor 29.9 VIP SYP ENO2 DLK1
6 ependymoblastoma 29.8 SYP MYCN ENO2
7 constipation 29.8 VIP TH S100B NPY
8 carcinoid syndrome 29.8 SYP NPY ENO2
9 horner's syndrome 29.7 VIP TH MYCN ENO2
10 malignant pheochromocytoma 29.7 TH SYP ENO2
11 adrenal neuroblastoma 29.7 SYP NTRK1 MYCN ENO2
12 paraganglioma 29.7 TH SYP S100B ENO2
13 small cell carcinoma 29.6 SYP MYCN ENO2 ALK
14 cervical neuroblastoma 29.6 VIP SYP MYCN ENO2
15 pheochromocytoma 29.6 VIP TH SYP NTRK1 NPY ENO2
16 ganglioneuroma 29.4 VIP TH SYP S100B NTRK2 NTRK1
17 ganglioglioma 28.9 TH SYP S100B NTRK2 MYCN ENO2
18 leukemia, acute myeloid 28.9 NTRK1 MYCN KDM4C CD44 BRCA1 ALK
19 rhabdomyosarcoma 28.9 SYP S100B MYCN ENO2 CD44 BRCA1
20 hirschsprung disease 1 28.7 VIP SYP PHOX2B NTRK1 NPY ENO2
21 neuroblastoma 28.6 VIP TH SYP PHOX2B NTRK2 NTRK1
22 medulloblastoma 27.8 SYP S100B NTRK2 NTRK1 MYCN KDM4C
23 hirschsprung disease ganglioneuroblastoma 11.2
24 peripheral nervous system ganglioneuroblastoma 11.2
25 mediastinum ganglioneuroblastoma 11.1
26 adrenal gland ganglioneuroblastoma 11.1
27 intermixed schwannian stroma-rich ganglioneuroblastoma 10.9
28 stroma-dominant and stroma-poor composite ganglioneuroblastoma 10.9
29 schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma 10.9
30 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 10.3 BRCA1 ALK
31 adrenal gland pheochromocytoma 10.3
32 desmoplastic infantile ganglioglioma 10.3 SYP MYCN
33 sarcomatoid transitional cell carcinoma 10.3 SYP ALK
34 multiple mucosal neuroma 10.3 NTRK1 ENO2
35 somatization disorder 10.3 HTR1A CRH
36 malignant melanocytic neoplasm of the peripheral nerve sheath 10.3 SYP ENO2
37 anal neuroendocrine tumor 10.3 SYP ENO2
38 optic nerve astrocytoma 10.3 SYP ENO2
39 cerebral neuroblastoma 10.3 SYP ENO2
40 neuronal intestinal dysplasia, type b 10.3 SYP ENO2
41 diarrhea 10.3
42 malignant giant cell tumor of the tendon sheath 10.3 NTRK2 NTRK1 ALK
43 lung meningioma 10.3 SYP ENO2
44 sinonasal undifferentiated carcinoma 10.3 SYP ENO2
45 auditory system benign neoplasm 10.3 SYP ENO2
46 pediatric fibrosarcoma 10.3 NTRK2 NTRK1 ALK
47 papillary tumor of the pineal region 10.3 SYP ENO2
48 congenital fibrosarcoma 10.3 NTRK2 NTRK1 ALK
49 auditory system cancer 10.3 SYP ENO2
50 cloacogenic carcinoma 10.3 SYP ENO2

Graphical network of the top 20 diseases related to Ganglioneuroblastoma:



Diseases related to Ganglioneuroblastoma

Symptoms & Phenotypes for Ganglioneuroblastoma

GenomeRNAi Phenotypes related to Ganglioneuroblastoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.93 ALK NTRK2
2 Decreased viability GR00221-A-2 9.93 BRCA1 NTRK2
3 Decreased viability GR00221-A-3 9.93 BRCA1 NTRK1
4 Decreased viability GR00221-A-4 9.93 ALK NTRK2
5 Decreased viability GR00240-S-1 9.93 CD44
6 Decreased viability GR00249-S 9.93 ALK NTRK1
7 Decreased viability GR00301-A 9.93 BRCA1 NTRK1
8 Decreased viability GR00381-A-1 9.93 HTR1A
9 Decreased viability GR00381-A-3 9.93 HTR1A
10 Decreased viability GR00386-A-1 9.93 SYP
11 Decreased viability GR00402-S-2 9.93 ENO2 HTR1A NPY
12 Increased the percentage of infected cells GR00402-S-1 8.62 CD44 WASF3

MGI Mouse Phenotypes related to Ganglioneuroblastoma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 ADM ALK BRCA1 CD44 CRH ENO2
2 homeostasis/metabolism MP:0005376 10.34 ADM ALK BRCA1 CD44 CRH DLK1
3 growth/size/body region MP:0005378 10.3 ALK BRCA1 CD44 CRH DLK1 ENO2
4 cellular MP:0005384 10.24 ADM BRCA1 CD44 CRH DLK1 ENO2
5 endocrine/exocrine gland MP:0005379 10.18 ADM ALK BRCA1 CD44 CRH GALP
6 mortality/aging MP:0010768 10.13 ADM ALK BRCA1 CD44 DLK1 HTR1A
7 nervous system MP:0003631 10.07 ALK BRCA1 CD44 CRH ENO2 HTR1A
8 integument MP:0010771 10.06 ADM ALK BRCA1 CD44 CRH KDM4C
9 liver/biliary system MP:0005370 9.97 ADM CD44 CRH DLK1 MYCN NPY
10 normal MP:0002873 9.97 ALK BRCA1 CD44 CRH MYCN NPY
11 respiratory system MP:0005388 9.7 ADM ALK BRCA1 CD44 CRH ENO2
12 vision/eye MP:0005391 9.28 ALK CD44 DLK1 MYCN NTRK1 NTRK2

Drugs & Therapeutics for Ganglioneuroblastoma

Drugs for Ganglioneuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Crizotinib Approved Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
2
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
3
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
4 Protein Kinase Inhibitors Phase 3
5 Keratolytic Agents Phase 3
6 Podophyllotoxin Phase 3 518-28-5
7
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
8
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
9
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
10
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
11
Melphalan Approved Phase 2 148-82-3 4053 460612
12
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
13
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
14
Daunorubicin Approved Phase 2 20830-81-3 30323
15
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
16
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
17
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
18
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
19
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
20
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
21
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
22
Eflornithine Approved, Withdrawn Phase 2 70052-12-9 3009
23
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 444795 5538
24
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
25
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
26
Ornithine Approved, Nutraceutical Phase 2 70-26-8, 3184-13-2 6262
27
MK-1775 Investigational Phase 1, Phase 2 955365-80-7, 501-36-0 24856436 445154
28
Molgramostim Investigational Phase 2 99283-10-0
29
Camptothecin Experimental Phase 2 7689-03-4
30 razoxane Phase 2
31 Nutrients Phase 2
32 Cardiotonic Agents Phase 2
33 Micronutrients Phase 2
34 retinol Phase 2
35 Trace Elements Phase 2
36 Protective Agents Phase 2
37 Retinol palmitate Phase 2
38 Vitamins Phase 2
39 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione Phase 2
40 Nitrogen Mustard Compounds Phase 2
41 Antifungal Agents Phase 2
42 topoisomerase I inhibitors Phase 2
43 Ch14.18 monoclonal antibody Phase 2
44 Immunologic Factors Phase 2
45 Immunoglobulins Phase 2
46 Alkylating Agents Phase 2
47 Antibodies Phase 2
48 Antibodies, Monoclonal Phase 2
49 Anti-Infective Agents Phase 2
50 Antiparasitic Agents Phase 2

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) Recruiting NCT03126916 Phase 3 Busulfan;Carboplatin;Cisplatin;Crizotinib;Cyclophosphamide;Dexrazoxane Hydrochloride;Doxorubicin Hydrochloride;Etoposide Phosphate;Isotretinoin;Melphalan Hydrochloride;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate
2 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma Recruiting NCT02176967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide
3 A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma Recruiting NCT04385277 Phase 2 Irinotecan;Isotretinoin;Temozolomide
4 A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma Active, not recruiting NCT03786783 Phase 2 Carboplatin;Cisplatin;Cyclophosphamide;Dexrazoxane;Doxorubicin;Etoposide;Isotretinoin;Melphalan;Thiotepa;Topotecan;Vincristine
5 A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma Active, not recruiting NCT01767194 Phase 2 Irinotecan Hydrochloride;Temozolomide;Temsirolimus
6 A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors Active, not recruiting NCT02095132 Phase 1, Phase 2 Adavosertib;Irinotecan Hydrochloride
7 A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory, or Progressive Neuroblastoma Suspended NCT03794349 Phase 2 Eflornithine Hydrochloride;Irinotecan Hydrochloride;Temozolomide
8 A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma Using Autologous T-cells Lentivirally Transduced to Express CD171-specific Chimeric Antigen Receptors Recruiting NCT02311621 Phase 1
9 Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma Recruiting NCT03434262 Phase 1 Gemcitabine;ribociclib;sonidegib;trametinib
10 International Congenital Central Hypoventilation Syndrome (CCHS) REDCap Registry Recruiting NCT03088020
11 Utility of Gallium-68-DOTA-Octreotate PET/CT in the Characterization of Pediatric Neuroendocrine Tumors Recruiting NCT04040088 Early Phase 1 Gallium Ga 68-DOTATATE
12 Neuroblastoma Biology Studies Recruiting NCT00904241
13 Phase II Study of Proton Radiation Therapy for Neuroblastoma Recruiting NCT02112617
14 A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma Active, not recruiting NCT01175356 cyclophosphamide;topotecan hydrochloride;cisplatin;etoposide phosphate;vincristine sulfate;doxorubicin hydrochloride;busulfan;melphalan;isotretinoin

Search NIH Clinical Center for Ganglioneuroblastoma

Cochrane evidence based reviews: ganglioneuroblastoma

Genetic Tests for Ganglioneuroblastoma

Anatomical Context for Ganglioneuroblastoma

MalaCards organs/tissues related to Ganglioneuroblastoma:

40
Brain, Eye, Adrenal Gland, Spinal Cord, Bone Marrow, T Cells, Ovary

Publications for Ganglioneuroblastoma

Articles related to Ganglioneuroblastoma:

(show top 50) (show all 757)
# Title Authors PMID Year
1
[The prognostic significance of P-glycoprotein in children with acute lymphoblastic leukemia and neuroblastoma]. 54 61
15828306 2005
2
TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. 54 61
15386308 2004
3
Paraneoplastic syndromes in ganglioneuroblastoma: contrasting symptoms of constipation and diarrhoea. 61 54
12739135 2003
4
Genomic organization and expression profile of the human and mouse WAVE gene family. 54 61
12856283 2003
5
Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. 61 54
12576454 2003
6
WAVE3, an actin-polymerization gene, is truncated and inactivated as a result of a constitutional t(1;13)(q21;q12) chromosome translocation in a patient with ganglioneuroblastoma. 54 61
12185600 2002
7
CD44 expression in neuroblastoma and related tumors. 54 61
9256826 1997
8
Multiple-hormone gene expression in ganglioneuroblastoma with watery diarrhea, hypokalemia, and achlorhydria syndrome. 61 54
7682155 1993
9
N-myc gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma). 61 54
8454274 1993
10
Neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma and neuroblastoma. 54 61
1327637 1992
11
Histopathologic features of composite ganglioneuroblastoma. Immunohistochemical distinction of the stromal component is related to prognosis. 61 54
2295048 1990
12
Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma. 61
33314708 2021
13
Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. 61
33809255 2021
14
Composite phaeochromocytomas-a systematic review of published literature. 61
33651160 2021
15
Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis. 61
33595736 2021
16
Primary renal ganglioneuroblastoma mimicking Wilms' tumor in a 3-year-old girl. 61
33421229 2021
17
Expression of BARD1 β Isoform in Selected Pediatric Tumors. 61
33530592 2021
18
Importance of Magnetic Resonance Imaging With Diffusion-weighted Imaging in Guiding Biopsy of Nodular Ganglioneuroblastoma: A Case Report. 61
31815883 2021
19
Ganglioneuroblastoma u dziecka z przewlekłym bólem brzucha ‒ opis przypadku. 61
33745248 2021
20
Diagnostic values of 68Ga-labelled DOTANOC PET/CT imaging in pediatric patients presenting with paraneoplastic opsoclonus myoclonus ataxia syndrome. 61
33409780 2021
21
Feasibility and possible value of quantitative semi-automated diffusion weighted imaging volumetry of neuroblastic tumors. 61
33334369 2020
22
Suprasellar central nervous system ganglioneuroblastoma: a case in a 9-year-old child and review of the literature. 61
32246193 2020
23
Primary orbital ganglioneuroblastoma in a child: A case report. 61
33157934 2020
24
Comparison of Incidence and Outcomes of Neuroblastoma in Children, Adolescents, and Adults in the United States: A Surveillance, Epidemiology, and End Results (SEER) Program Population Study. 61
33249420 2020
25
High-dose 131I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience. 61
32862362 2020
26
Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma. 61
33172452 2020
27
Brain paraneoplastic syndromes in a patient with mediastinal ganglioneuroma. 61
32944100 2020
28
Primary round cell sarcomas of the urinary bladder with EWSR1 rearrangement: a multi-institutional study of thirteen cases with a review of the literature. 61
32798549 2020
29
Harlequin syndrome associated with ganglioneuroblastoma-induced Horner syndrome. 61
33125512 2020
30
Robotic adrenalectomy in the pediatric population: initial experience case series from a tertiary center. 61
33028284 2020
31
Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors. 61
32728700 2020
32
MYC-associated protein X binding with the variant rs72780850 in RNA helicase DEAD box 1 for susceptibility to neuroblastoma. 61
32915406 2020
33
Retrospective accuracy analysis of MRI based lesion size measurement in neuroblastic tumors: which sequence should we choose? 61
32912148 2020
34
Adult-onset ganglioneuroblastoma of the posterior mediastinum with osseous metastasis. 61
32714482 2020
35
Diagnostic Use of Post-therapy 131I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma. 61
32887257 2020
36
Incidence, Treatment, and Survival in Primary Central Nervous System Neuroblastoma. 61
32344130 2020
37
Incidence and outcomes of neuroblastoma in Australian children: A population-based study (1983-2015). 61
32068329 2020
38
Retroperitoneal Ganglioneuroma in a Patient Presenting With Vague Abdominal Pain. 61
32789073 2020
39
Central nervous system ganglioneuroblastoma harboring MYO5A-NTRK3 fusion. 61
32556925 2020
40
Neurogenic Tumors of the Mediastinum. 61
32448592 2020
41
Embryonal Tumors of the Central Nervous System: An Update. 61
32389264 2020
42
Pediatric neuroblastic tumors: A critical evaluation of cytomorphological features for risk stratification on aspiration cytology. 61
32043835 2020
43
Tatton-Brown-Rahman syndrome: Six individuals with novel features. 61
31961069 2020
44
Therapeutic results in three cases of ganglioneuroblastoma associated with opsoclonus myoclonus ataxia syndrome. 61
31898588 2020
45
Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells. 61
31922656 2020
46
Posterior mediastinal ganglioneuroblastoma in an adolescent: A case report and review. 61
31837198 2020
47
The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma. 61
31612589 2020
48
Adrenal masses in children: Imaging, surgical treatment and outcome. 61
30962018 2020
49
Rare Cases of Pediatric Vasoactive Intestinal Peptide Secreting Tumor With Literature Review: A Challenging Etiology of Chronic Diarrhea. 61
32850544 2020
50
A Rare Cause of Sleep-Disordered Breathing: ROHHAD Syndrome. 61
33330273 2020

Variations for Ganglioneuroblastoma

ClinVar genetic disease variations for Ganglioneuroblastoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TSC2 NM_000548.5(TSC2):c.646G>A (p.Glu216Lys) SNV Uncertain significance 49379 rs45517118 GRCh37: 16:2106243-2106243
GRCh38: 16:2056242-2056242
2 ALK NM_004304.5(ALK):c.3271G>A (p.Asp1091Asn) SNV Uncertain significance 218628 rs864309584 GRCh37: 2:29446296-29446296
GRCh38: 2:29223430-29223430
3 BRCA1 NM_007294.4(BRCA1):c.1243G>A (p.Val415Ile) SNV Uncertain significance 142855 rs587782770 GRCh37: 17:41246305-41246305
GRCh38: 17:43094288-43094288

Expression for Ganglioneuroblastoma

Search GEO for disease gene expression data for Ganglioneuroblastoma.

Pathways for Ganglioneuroblastoma

Pathways related to Ganglioneuroblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.86 VIP TH SYP S100B NTRK2 NTRK1
2 11.67 TH PHOX2B NTRK2 HTR1A
3 11.15 TH SYP S100B CD44
4
Show member pathways
10.3 NTRK2 NTRK1

GO Terms for Ganglioneuroblastoma

Cellular components related to Ganglioneuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 terminal bouton GO:0043195 9.13 TH SYP NTRK2
2 perikaryon GO:0043204 8.92 VIP TH ENO2 CRH

Biological processes related to Ganglioneuroblastoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.88 NTRK2 MYCN KDM4C CRH BRCA1
2 cerebral cortex development GO:0021987 9.63 TH NTRK2 NPY
3 sympathetic nervous system development GO:0048485 9.51 PHOX2B NTRK1
4 synaptic transmission, dopaminergic GO:0001963 9.49 TH CRH
5 positive regulation of kinase activity GO:0033674 9.46 NTRK2 NTRK1 CD44 ALK
6 cellular response to nicotine GO:0071316 9.43 TH NTRK1
7 response to ether GO:0045472 9.4 TH CRH
8 mechanoreceptor differentiation GO:0042490 9.37 NTRK2 NTRK1
9 neurotrophin signaling pathway GO:0038179 9.32 NTRK2 NTRK1
10 regulation of serotonin secretion GO:0014062 9.26 HTR1A CRH
11 learning or memory GO:0007611 9.26 VIP S100B NTRK1 CRH
12 positive regulation of cell proliferation GO:0008284 9.17 VIP S100B NTRK2 KDM4C HTR1A CRH

Molecular functions related to Ganglioneuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 NTRK2 NTRK1 ALK
2 neurotrophin binding GO:0043121 9.26 NTRK2 NTRK1
3 neurotrophin receptor activity GO:0005030 9.16 NTRK2 NTRK1
4 neuropeptide hormone activity GO:0005184 9.13 VIP NPY CRH
5 hormone activity GO:0005179 9.02 VIP NPY GALP CRH ADM

Sources for Ganglioneuroblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....